Fox Business - The Power to Prosper
Search Site

AstraZeneca

David, Goliath Team Up to Cure Rare Diseases

In the world of drug development, collaboration is key.When Kathy Giusti was diagnosed with a rare and fatal blood cancer nearly 20 years ago, there wasn't a single drug in the pipeline to help her fight her grim prognosis, and she was expected to die within three years. That is until the then-new mother found determination, launching the Multiple Myeloma Research Foundation , which now is helping to develop 20 treatments at various stages in the pipeline.Like Giusti, Ilan Ganot is facing a similar tragic circumstance. At just two-years old, his son was diagnosed with Duchenne muscular dystrophy, a muscular degenerative disease that usually kills those it affects by their teen or early adult years. Rather than sit and wait for his son to die, Ganot quit his job as a banker at JPMorgan Chase (NYSE:JPM), devoting his life to finding a cure and starting his own firm called Solid Ventures .The treatments for more common ailments like asthma, diabetes, and depression are well known and ofte...

Read More

  1. AstraZeneca to Buy Bristol's Stake in Venture

    AstraZeneca (NYSE:AZN) agreed on Thursday to buy Bristol-Myers Squibb's (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.The London-based biop...

  2. European Stocks Rally After U.S. Fed Tapers

    European stock indexes rallied at the open on Thursday as markets interpreted the U.S. Federal Reserve's taper decision as confidence in the underlying strength in t...

  3. Facebook Shares Slammed, And Other #Stocks2Watch

    Facebook [FB]Facebook took a beating after the social-networking giant revealed a 70-million-share follow-on offering, in which chief executive Mark Zuckerberg will ...

  4. GlaxoSmithKline To Stop Paying Doctors To Promote Drugs

    GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff - a first for an industry battling scandals o...

  5. Horizon to Market AstraZeneca Arthritis Drug in $35M Deal

    Horizon Pharma Inc said it would buy the right to market AstraZeneca Plc's arthritis drug Vimovo in the United States for an upfront payment of $35 million, sending ...

  6. Merck Invests $107M in China Drug Plant

    German drugmaker Merck KGaA has invested 80 million euros ($107.67 million) in a manufacturing plant in China, the company said on Friday, underlining the importance...

  7. New guidelines would put more Americans on cholesterol drugs

    FOX News Medical A-Team’s Dr. Marc Siegel weighs in on the new cholesterol guidelines.

  8. AstraZeneca Appoints New CFO as Profit Falls

    AstraZeneca (NYSE:AZN) appointed former GlaxoSmithKline (NYSE:GSK) executive Marc Dunoyer as chief financial officer on Thursday and revealed an 18% decline in third...

  9. GSK's Reilly assisting anti-bribery authorities in China

    Mark Reilly, GlaxoSmithKline's former head of operations in China, is helping anti-corruption officials in the country who are investigating allegations of extensive...

  10. Eli Lilly Downgraded To Underperform By Jefferies

    Analysts at Jefferies downgraded three major pharmaceutical companies Friday, citing deteriorating business fundamentals. Eli Lilly & Co. was cut to underperform fro...

  11. Summer deals lift banks' hopes of M&A tipping point

    Verizon's deal to buy Vodafone out of their U.S. wireless venture for $130 billion may have been years in the making, but bankers hope it could be an inflexion point...

  12. Stocks Slip On Heels of Kerry's Syria Speech

    FOX Business: Capitalism Lives HereThe markets slid into the red on Monday after Secretary of State John Kerry said chemical weapons were used in Syria. Today's Mark...

  1. Monica Crowley’s take on the GM scandal

    FOX News contributor Monica Crowley on the GM scandal and Wall Street.

  2. AstraZeneca Raises Bet On Japan, Buys Sumitomo

    AstraZeneca has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K.The British gr...

  3. Firms Race for Slice of $7.5B Asthma Market

    Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a ne...

  4. European Stocks Slide For Third Day

    European stock markets opened with broad-based losses on Friday, as ongoing tensions in Ukraine and worries about slowing economic growth in China hampered the inves...

  5. AstraZeneca Says Generics to Dent '14 Profits

    AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from ...

  6. Bristol-Myers 4Q Earnings Beat the Street

    Bristol-Myers Squibb (NYSE:BMY) reported a 21% drop in its fourth-quarter profit, a year after the drug company logged a significant tax benefit.Bristol-Myers said F...

  7. AstraZeneca Forecasts Faster Return To Growth

    AstraZeneca expects new drugs and a recent diabetes deal to offset a wave of patent expiries and return it to growth faster than analysts predict, with 2017 revenue ...

‹ Prev12345Next ›
Freebase CC-BY
Source: AstraZeneca on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL